Notification of trade among primary insider
Reference is made to the notice to the stock exchange on 3 November 2010 regarding commencement of subscription period for the “Subsequent repair offering”. On 15 November 2010 mandatory notification of trade among primary insiders of DiaGenic ASA took place. The transaction is described in detail below.
Erik Anders Lönneborg, Director in DiaGenic ASA, received 3,107,397 subscription rights in the subsequent repair issue. Lönneborg has sold 2,900,000 subscription rights at an average price of NOK 0.1296 per subscription right, and subscribed for 207,397 shares in the subsequent repair offering at NOK 0.50 per share. Lönneborg`s overall holding in the Company will increase from 2,907,370 shares to 3,114,767 shares post allotment of the shares in the offering.
Erik Christensen, CEO
Telephone: 47 95939918
About DiaGenic ASA
DiaGenic is an innovative Norwegian biotechnology company that seeks to create value for patients, partners, and investors by developing new and more patient friendly methods for early detection of diseases. DiaGenic is currently a world leader in analyzing gene expression signatures related to disease in easily available clinical samples such as peripheral blood. This unique method is based on the principle that even when a disease is localized at a specific part of the body, secondary responses, which are also characteristic of the disease, can be measured in other parts of the body. DiaGenic has developed and CE marked two blood based diagnostic tests, BCtect® for early breast cancer detection and ADtect® for early detection of Alzheimer’s Disease. The company protects its technology through an extensive patent portfolio. DiaGenic promotes its products towards leading pharmaceutical and imaging companies, and towards clinicians. DiaGenic is listed on the Oslo Stock Exchange. For more information visit www.diagenic.com